Objective To explore the value of CT in the preoperative assessment of resectability of advanced gastric carcinoma.Methods The relation of CT findings and operative data in 93 cases of advanced gastric carcinoma were retrospectively analyzed.Results There were 23 cases of fundus and cardia carcinoma,59 cases of carcinoma of gastric corpus,and 11 cases of carcinoma of antrum.All cases showed increased thickness of gastric wall in various degrees,some of the cases showed tumor growth in the gastric wall,ulcer of the mucosa,stricture of gastric cavity and cardia,increased thickness of cardiac wall,and invasion of lower esophagus and perigastric organs.The accuracy of location and definitive diagnosis by CT,compared to gastroscopic biopsy and postoperative pathology,was considerable,and the detecting rate of tumor by CT was 100 %.CT had important reference value in preoperative evaluation of tumor resectability.The excision rate in the predicted operable group was 93.3 %;in the predicted unresectable group,the non-excision rate was 75.0%.Conclusions Preoperative CT diagnosis of gastric carcinoma has important clinical significance.CT provides a high reference value for assessing the resectability of gastric carcinoma,and it is worthy of widespread use.

Objectives: An Asian Gynecologic Oncology Group phase III randomized trial was conducted to determine whether maintenance chemotherapy could improve progression-free survival (PFS) in stages III/IV ovarian cancer. Methods: Between 2007 and 2014, 45 newly-diagnosed ovarian cancer patients were enrolled after complete remission and randomized (1:1) to arm A (4-weekly carboplatin area under the curve 4 and pegylated liposomal doxorubicin [PLD] 30 mg/m2, n=24) for 6 cycles or arm B (observation, n=21). The primary end-point was PFS. A post hoc translational study was conducted to deep sequence BRCA/homologous recombination deficiency (HRD) genes, because BRCA/HRD mutations (BRCA/HRDm) are known to be associated with better prognosis. Results: Enrollment was slow, accrual was closed when 7+ years had passed. With a medianfollow-up of 88.9 months, the median PFS was significantly better in arm A (55.5 months) than arm B (9.2 months) (hazard ratio [HR]=0.40; 95% confidence interval [CI]=0.19–0.87; p=0.020), yet the median overall survival was not significantly different in arm A (not reached) than arm B (95.1 months) (p=0.148). Overall grade 3/4 adverse events were more frequent in arm A than arm B (60.9% vs 0.0%) (p<0.001). Quality of life was generally not significantly different. Distribution of BRCA1/2m or BRCA/HRDm was not significantly biased between the two arms. Wild-type BRCAon-HRD subgroup seemed to fare better with maintenance therapy (HR=0.35; 95% CI=0.11–1.18; p=0.091). Conclusions Despite limitations in small sample size, it suggests that maintenance carboplatin-PLD chemotherapy could improve PFS in advanced ovarian cancer.

Arm ; Asian Continental Ancestry Group ; Bias (Epidemiology) ; Carboplatin ; Disease-Free Survival ; Doxorubicin ; Drug Therapy ; Follow-Up Studies ; Humans ; Maintenance Chemotherapy ; Ovarian Neoplasms ; Prognosis ; Quality of Life ; Recombination, Genetic ; Sample Size